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Vitamin K is essential for the activity of c-carboxyglutamate
(Gla)-proteins including matrix Gla28 protein and osteocalcin;
an inhibitor of vascular calcification and a bone matrix
protein, respectively. Insufficient vitamin K intake leads to the
production of non-carboxylated, inactive proteins and this
could contribute to the high risk of vascular calcification in
hemodialysis patients. To help resolve this, we measured
vitamin K1 and K2 intake (4-day food record), and the vitamin
K status in 40 hemodialysis patients. The intake was low in
these patients (median 140lg/day), especially on days of
dialysis and the weekend as compared to intakes reported
in a reference population of healthy adults (mean K1 and
K2 intake 200lg/day and 31lg/day, respectively). Non-
carboxylated bone and coagulation proteins were found to
be elevated in 33 hemodialysis patients, indicating subclinical
hepatic vitamin K deficiency. Additionally, very high non-
carboxylated matrix Gla28 protein levels, endemic to all
patients, suggest vascular vitamin K deficiency. Thus,
compared to healthy individuals, hemodialysis patients
have a poor overall vitamin K status due to low intake.
A randomized controlled trial is needed to test whether
vitamin K supplementation reduces the risk of arterial
calcification and mortality in hemodialysis patients.
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Vitamin K is necessary for the function of proteins contain-
ing g-carboxyglutamate (Gla) residues. Well-known vitamin
K–dependent proteins (Gla proteins) are vitamin K–depen-
dent coagulation factorsthat are mainly synthesized in the
liver. Extrahepatic Gla proteins are osteocalcin (OC), synthe-
sized in bone, and matrix Gla protein (MGP), synthesized in
the vasculature and cartilage. Gla residues are formed during
a vitamin K–dependent posttranslational carboxylation reac-
tion and are essential for the activity of Gla proteins.1 Insuf-
ficient dietary intake of vitamin K will lead to the production
of uncarboxylated (i.e., inactive) proteins.2
MGP synthesized by vascular smooth muscle cells is the
strongest physiological inhibitor of vascular calcification cur-
rently known. Deficiency of carboxylated MGP may con-
tribute substantially to the development and progression of
arterial calcification. Vascular calcifications are found in
60–80% of hemodialysis (HD) patients3,4 and are associated
with a high cardiovascular risk, independent of traditional
atherogenic risk factors.5,6 Areas of calcification in vascular
tissue are associated with accumulation of uncarboxylated MGP
species, which has also been found to precede the
development of clinically overt calcification in children on
dialysis.7
Vitamin K intake may be differentiated for the intake of
vitamin K1 (phylloquinone) and vitamin K2 (group name for
menaquinones). The estimated daily vitamin K1 intake is
200±98 mg and for vitamin K2 it is 31±7mg in the general
population.8–10 Vitamin K1 and K2 content of food products
has been extensively studied by our laboratory in the past,11
resulting in a comprehensive dietary vitamin K1 and K2
database. Previous studies using this database demonstrated
that intake of vitamin K2 was inversely associated with cardi-
ovascular calcification and mortality.12–14
Systemic vitamin K status can be determined by measur-
ing (1) circulating vitamin K1 and K2 levels and (2) circulat-
ing inactive forms of vitamin K–dependent proteins. Intake of
vitamin K–containing food products will readily influence
measurements of circulating vitamin K levels. In contrast,
measurements of uncarboxylated prothrombin (known as
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protein induced by vitamin K absence/antagonism II (PIVKA-II)),
uncarboxylated OC (ucOC), and desphospho-uncarboxy-
lated (dp-uc) MGP will reflect utilization of vitamin K in
tissues. We recently developed a new MGP assay to measure
the dp-ucMGP species. First results show that this inactive,
immature MGP species is suited to assess extrahepatic
vitamin K status, particularly in the vasculature.15
In the present study, we aimed to investigate vitamin K1
and K2 intake as well as vitamin K status in HD patients.
Vitamin K intake was estimated using a comprehensive
dietary vitamin K database.12,13 Vitamin K status was
evaluated with measurements of circulating vitamin K1 and
K2 levels, as well as of hepatic and extrahepatic vitamin
K–dependent proteins, including PIVKA-II, MGP, and OC.
With the present study, we expected to obtain new insights in
different aspects of vitamin K metabolism in HD patients,
and to increase our knowledge on the risk factors and
pathogenesis of arterial calcification in these patients.
Additionally, the results of this study will give an indication
whether HD patients may benefit from an increased dietary
vitamin K intake.
RESULTS
Patient population
Vitamin K intake and status were investigated in the entire
cohort of 40 HD patients, consisting of 22 male and 18
female patients with a mean age of 62±16 years. The median
(range) dialysis vintage was 40 (4–385) months. All baseline
characteristics of the patient population are presented in
Table 1. As expected, the prevalence of cardiovascular disease
(CVD) and hypertension was high. Control of calcium and
phosphorus was quite well.
Vitamin K intake
Total vitamin K intake of patients, registered during 4 days,
was 140 (30–546) mg/day, consisting of 118 (18–494) mg/day
vitamin K1 and 21 (2–68) mg/day vitamin K2 (Table 2). As
expected, total vitamin K intake was predominantly deter-
mined by the intake of vitamin K1. One-third of the patients
(n¼ 13; 33%) had an average total vitamin K intake of
o100 mg/day. Total vitamin K intake was considerably lower
on weekend days and dialysis days (Table 2), as compared
with week days (P¼ 0.003 for both comparisons). These
differences originated from differences in vitamin K1 intake
between these day-types (P¼ 0.003 for both comparisons),
without significant differences in vitamin K2 intake.
There were no differences in total vitamin K, K1, or K2
intake between males and females, or between patients with
CVD or diabetes mellitus and patients without these con-
ditions (Table 2). In correlation analysis, total vitamin K
intake was not associated with age, body mass index, dialysis
vintage, or any of the biochemical characteristics.
Vitamin K status
Serum vitamin K1 concentration showed a broad range (Table 3).
Almost half of the patients (n¼ 18; 45%) had circulating
vitamin K1 levels below the lower limit of normal range. Of
the menaquinones (vitamin K2), only MK-4 was measurable
in low quantities in the blood. MK-5 through MK-10 were
Table 1 | Characteristics of the 40 HD patients
Age (years) 65 (23–86)
Sex (male/female ratio) 22/18
Dialysis vintage (months) 40 (4–385)
Cause of ESRD
Glomerular disease 9 (23)
Vascular disease, hypertension 10 (25)
Polycystic kidney disease 9 (23)
Diabetic kidney disease 2 (5)
Miscellaneous 6 (15)
Unknown 4 (10)
Hypertension 27 (67.5)
Diabetes 6 (15.0)
Current smoking 6 (15.0)
BMI (kg/m2) 24.6±3.7
Cardiovascular disease 15 (37.5)
Coronary artery disease 10 (25.0)
Peripheral artery disease 5 (12.5)
Cerebrovascular disease 4 (10)
History of renal transplantation 7 (17.5)
History of parathyroidectomy 5 (12.5)
Hb (mmol/l) 7.2±0.8
Ca (mmol/l) 2.3±0.2
P (mmol/l) 1.6±0.3
Ca P (nmol2/l2) 3.6±0.8
AP (U/l) 72±23
PTH (pmol/l) 15 (1–94)
Cholesterol (mmol/l) 4.0±1.0
Triglycerides (mmol/l) 1.9±0.8
Vitamin D supplementation 37 (92.5%)
Cinacalcet 4 (10)
Oral PB 35 (87.5)
41 Oral PB 20 (50)
Ca-containing PB 16 (40)
Non-Ca-containing PB 29 (72.5)
Antihypertensive medication 28 (70)
41 Medication 10 (25)
Iron supplementation 38 (95)
Darbepoetin alpha 37 (92.5)
Dietary intake
Total energy (kJ/day) 7502±2119
Total protein (g/day) 66±8.5
Total fat (g/day) 62±9
Monounsaturated fat (g/day) 21±4
Polyunsaturated fat (g/day) 11±3
Saturated fat (g/day) 26±5
Fiber (g/day) 20±12
Ca (mg/day) 814±235
Vitamin C (mg/day) 68±31
Abbreviations: AP, alkaline phosphatase; BMI, body mass index; Ca, calcium; ESRD,
end-stage renal disease; Hb, hemoglobin; HD, hemodialysis; P, phosphorus; PB,
phosphate binders; PTH, parathyroid hormone.
Data are given as mean±s.d., median (range), or as absolute numbers with
percentage of total between parentheses. Cardiovascular disease was defined as a
history of coronary artery disease (myocardial infarction, angina pectoris, or
evidence of obstructive disease by angiography), cerebrovascular disease (throm-
botic stroke or transient ischemic attack), calcific aortic valve disease, or peripheral
artery disease (a history of claudication or lower extremity revascularization).
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undetectable in the circulation of the patients (Table 3).
Hepatic vitamin K status, as assessed with PIVKA-II mea-
surement, was suboptimal in the patient cohort. Thirty-three
patients (82.5%) had elevated PIVKA-II levels. The median
level of 3.8 (1.4–12.4) ng/ml was almost twice the upper normal
level. Plasma PIVKA-II levels were not associated with any of
the baseline characteristics.
Extrahepatic vitamin K status was assessed by dp-ucMGP
and OC measurements, reflecting vascular and bone vitamin
K status, respectively. Plasma dp-ucMGP levels were elevated
in all 40 patients (Table 3), indicating suboptimal vascular
vitamin K status in the entire patient cohort. The dp-ucMGP
levels were positively correlated with dialysis vintage (Spearman’s
rho¼ 0.440, P¼ 0.035). In addition, patients with CVD had
significantly higher dp-ucMGP levels (2226±1103 pmol/l)
compared with patients without CVD (1653±626 pmol/l;
P¼ 0.034). The mean ucOC level was considerably increased
compared with average levels found in healthy reference
subjects aged 440 years (Table 3). However, as carboxylated
OC (cOC) levels were also elevated, the average ucOC/cOC
ratio was 0.5, which is within the normal range.
When investigating the associations between the different
parameters for vitamin K status, plasma dp-ucMGP levels
were positively correlated with PIVKA-II levels (Spearman’s
rho¼ 0.384, P¼ 0.028). There were no other significant
correlations. Investigation of the associations between
vitamin K intake (total, K1, and K2) and measurement of
vitamin K status, revealed no significant associations.
DISCUSSION
This is the first study fully assessing vitamin K intake and
status in HD patients. The main finding was that vitamin K
intake in the present HD patient cohort was estimated at
140 mg/day, mainly from vitamin K1. The second important
finding is that both hepatic as well as extrahepatic vitamin K
status were strikingly poor, with the most extreme situation
for the vascular wall.
Dietary intake of vitamin K in patients was below values
previously found in a reference population of healthy adults
(mean vitamin K1 intake 200 mg/day, and vitamin K2 intake
31 mg/day in the Netherlands).8–10 Of note, a different
method was used in these studies, that is, a food-frequency
questionnaire to estimate vitamin K intake. We have recently
performed a study among 60 Dutch healthy volunteers using
a similar 3-day food record. In this (yet unpublished) study,
the intake of vitamin K1 was 191 mg/day and for vitamin K2 it
was 24.8 mg/day. As these values are consistent with the pre-
vious studies in healthy population using a food-frequency
questionnaire, it is unlikely that the difference in vitamin K
intake between healthy population and HD patients is due to
methodological differences. Low vitamin K intake of HD
patients may be related to the dietary regimen generally pre-
scribed for HD patients, which includes restriction of sodium
and potassium intake.16 Sodium is present in cheese and
potassium is abundantly present in green vegetables, which
are the food products containing abundant amounts of
vitamin K1 and K2, respectively. Nevertheless, vitamin K
intake of our patients was still higher than might have been
expected as it was previously predicted that a typical renal
diet would contain 80 mg or less of vitamin K per day.17 This
may be related to a relatively high green vegetable and cheese
intake in the Netherlands. Vitamin K intake was lower on
weekend days and dialysis days as compared with week days,
reflecting a different dietary pattern on these days. Consistent
with the literature, intake of vitamin K2 only accounts for the
minority of vitamin K intake.8–10 However, intake of vitamin
Table 2 | Vitamin K intake
Intake (lg/day) of energy-adjusted
vitamin K
Total Vitamin K1 Vitamin K2
Average all days 140 (30–546) 118 (18–494) 21 (2–68)
Day types
Week (Monday–Friday) 171 (41–888) 154 (19–882) 16 (2–58)
Weekend (Saturday, Sunday) 53 (13–1075) 21 (6–1064) 19 (0–111)
Hemodialysis 66 (5–452) 44 (5–425) 20 (0–85)
P o0.001 o0.001 0.624
Patients
Male (n=22) 115 (42–393) 96 (33–360) 19 (2–48)
Female (n=18) 178 (30–546) 144 (18–494) 22 (4–68)
P 0.289 0.302 0.471
With CVD (n=15) 113 (30–546) 93 (18–494) 18 (3–52)
Without CVD (n=25) 162 (42–413) 134 (18–385) 22 (2–68)
P 0.121 0.158 0.451
With DM 139 (66–292) 107 (47–272) 19 (4–48)
Without DM 140 (30–546) 123 (18–494) 22 (2–68)
P 0.791 0.910 0.691
Abbreviations: CVD, cardiovascular disease; DM, diabetes mellitus.
Vitamin K intakes (total, K1, and K2) are given for different day types (week, weekend,
and dialysis) and for different patient groups (female and male, with and without
CVD and DM). Data are given as median (range). P-values are based on
Kruskal–Wallis tests (for comparison of day types) and Mann–Whitney U-tests (for
comparison of patient groups).
Table 3 | Vitamin K status
HD patients Reference values
Circulating vitamin K (nmol/l)
Vitamin K1 0.30 (0.00–5.71) 0.029–2.65
MK-4 0.00 (0.00–1.13) oLower detection limit
MK-5 trough MK-10 0.00 (0.00–0.00) oLower detection limit
Hepatic vitamin K status
PIVKA-II (ng/ml) 3.8 (1.4–12.4) o2
Extrahepatic vitamin K status
dp-ucMGP (pmol/l) 1868±870 50–700
ucOC (ng/ml) 6.1±28 2–4
cOC (ng/ml) 11.7±2.8 5–9
Ratio ucOC/cOC 0.5 (0.1–0.9) o1.0
Abbreviations: cOC, carboxylated osteocalcin; dp-ucMGP, desphospho-uncarboxy-
lated MGP; HD, hemodialysis; MGP, matrix Gla protein; PIVKA-II, protein induced by
vitamin K absence/antagonism II; ucOC, uncarboxylated OC.
Values of different markers for vitamin K status are given: circulating vitamin K1 and
K2 levels, PIVKA-II levels for hepatic vitamin K status, and dp-ucMGP and OC levels
for extrahepatic vitamin K status. Reference values in healthy subjects are given
based on literature (vitamin K1 and K2 levels), information provided by manufacturer
of the assay (PIVKA-II), and measurements in healthy subjects aged above 40 years
(dp-ucMGP and OC). Data are given as mean±s.d. or median (range).
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K2 is probably highly relevant for cardiovascular health.
Vitamin K2 intake (and not vitamin K1) was inversely asso-
ciated with cardiovascular calcification and mortality in the
general population.12–14 Vitamin K2 is more uniformly distri-
buted over the various tissues, whereas vitamin K1 is prefer-
entially targeted to the liver.18 It has been shown for instance
that there is a higher accumulation and utilization of MK-4
in the vascular wall compared with vitamin K1.
19
Vitamin K status was investigated using measurements
of circulating vitamin K, PIVKA-II, dp-ucMGP, and OC.
Circulating vitamin K levels were below the normal range in
almost half of the patients. The majority of the menaqui-
nones (MK-5 through MK-13) were below the lower detec-
tion limit that is usually found in humans.20 It should be kept
in mind that circulating vitamin K concentrations fluctuate,
among others influenced by recent dietary intake. Also,
circulating vitamin K may not reflect the utilization of
vitamin K in tissue. The high PIVKA-II levels found in the
vast majority of patients indicate that vitamin K availability
in the liver is too low to produce fully carboxylated clotting
factors. Although an increased PIVKA-II level may not result
in clinical hemostatic problems, it indicates that the hepatic
vitamin K status is poor. The high dp-ucMGP levels found in
all patients confirm previous findings in HD patients15,21 and
indicate a poor vascular vitamin K status, which may well be
a contributing factor in cardiovascular calcification. Plasma
dp-ucMGP was the only marker that correlated with PIVKA-
II levels, stressing its value as a vascular biomarker for
vitamin K status. With respect to OC, both the ucOC and
cOC levels were high, resulting in a normal OC ratio. This
may be explained by retention of circulating OC (fragments)
in uremic serum.22,23 An alternative explanation may be that
end-stage renal disease–associated increased bone turnover
resulted in an overall increased OC synthesis. Further
investigations are needed to elucidate why both ucOC and
cOC levels measured with enzyme-linked immunosorbent
assays (ELISAs) are high in HD patients. Overall, the appli-
cation of OC measurements in HD patients seems to be
complicated and OC carboxylation may not be a useful
marker for vitamin K status in HD patients.22
In general, dietary vitamin K intake in healthy subjects
and HD patients is sufficient to maintain normal hemostasis,
but may not be sufficient for full carboxylation (activation)
of the extrahepatic Gla proteins. Booth and coworkers
showed in a cohort of 142 HD patients that vitamin K status
in this patient population is suboptimal.22 Low circulating
phylloquinone levels and poor OC carboxylation were found
in 29 and 93% of subjects, respectively. A recent study by the
same group in 172 subjects with stage 3–5 chronic kidney
disease, showed that the criteria for subclinical vitamin K
deficiency were met by 6% of the patients based on circulat-
ing K1 measurements, by 60% based on OC carboxylation,
and by 97% based on PIVKA-II levels.24 The present study
confirms these findings, with exception of poor OC carboxy-
lation. It should be noted, however, that OC carboxylation
was measured with a different technique (a radioimmunoassay
based on the different affinities of ucOC and cOC for
hydroxyapatite) in these studies from that used in the present
study (ELISAs based on monoclonal antibodies against ucOC
and cOC). Their outcomes may, therefore, not be comparable
with ours. Owing to its lipophilic characteristics and incor-
poration into lipoproteins, vitamin K is not expected to be
removed by HD treatment.9 It can, therefore, be hypothesized
that vitamin K deficiency in HD patients is due to a dimi-
nished dietary intake, which may increase the risk of arterial
calcification. Our study confirms that the dietary vitamin K
intake in HD patients is lower than that in the general
population, although we could not demonstrate a correlation
between vitamin K intake and markers for vitamin K status.
This might be because of the relatively low number of
patients.
The recommended daily allowance for vitamin K of 1mg/
day/kg bodyweight is based on intakes of vitamin K1 needed
to maintain adequate synthesis of blood coagulation factors.
The (higher) requirements of extrahepatic tissues for maximal
carboxylation of Gla proteins were not taken into account in
this recommendation, and although vitamin K intake met
this intake level for the majority of patients, it is clear that
this is too low for maximal carboxylation of extrahepatic Gla
proteins. Based on the elevated plasma levels of PIVKA-II, it
may even be concluded that the hepatic vitamin K status was
not adequate to fully support the carboxylation of the vitamin
K–dependent clotting factors. The design of the present study
does not allow to investigate whether factors other than low
dietary intake may cause insufficient vitamin K status and to
evaluate its long-term consequences. Further studies need to
be performed to confirm the present results in larger
cohorts of chronic kidney disease and dialysis patients,
including peritoneal dialysis patients. Also, it may be relevant
to evaluate kidney transplant recipients, because these
patients may well maintain their previous dietary habits as
dialysis patient.
What may be the clinical implications of our findings?
Improvement of vitamin K status in HD patients may readily
be achieved by food supplements. The bioavailability of
vitamin K from supplements is probably better than that
from most foods.20 For OC it is known that, although ucOC
is responsive to increased dietary vitamin K, a maximal response
can only be achieved with pharmacological vitamin K intakes.20
The most common vitamin K form in food supplements and
multivitamins is K1. Two commercially available K2 vitamins
are MK-4 and MK-7. The half-life of MK-7 (approximately 3
days), is much longer compared with that of MK-4 and K1,
with a steady-state plasma level reached after 2 weeks of daily
supplementation.25 In a pilot study among 53 HD patients,
the administration of MK-7 (dosage 45, 135, or 360 mg/day)
resulted in significantly decreased ucOC and dp-ucMGP
levels within 6 weeks.26 In the highest dosage group, the
response-to-treatment for dp-ucMGP levels was even 100%.
To improve the vitamin K status of HD patients, supple-
mentation may indeed be the best method, as increasing the
dietary intake of vitamin K is probably not possible because
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of the generally prescribed dietary regimen, as discussed
previously. As HD patients are generally prescribed multi-
vitamins, it may be relatively easy to add vitamin K to these
preparations. A contraindication for vitamin K supple-
mentation is the use of vitamin K antagonists (oral
anticoagulants).
In conclusion, HD patients have a poor overall vitamin K
status and vitamin K intake is low compared with healthy
Dutch subjects. The high dp-ucMGP levels are strongly
suggestive for vascular vitamin K insufficiency to a level that
the calcification-inhibitory activity of MGP is impaired,
which may contribute to the extremely high risk for arterial
calcification in HD patients. Together with preliminary data
that vitamin K supplementation may improve the carboxyla-
tion status of MGP, these data warrant a well-designed
controlled trial to test whether vitamin K supplementation
may reduce the risk of arterial calcification and may even
reduce mortality in HD patients.
MATERIALS AND METHODS
Patients
The study was performed between 1 October 2009 and 1 February
2010. There was no formal power calculation for this explorative
observational study. All patients who had been on regular three
times weekly, in-center HD treatment at the Dialysis Center
Groningen/University Medical Center Groningen for at least 3
months and who fulfilled the inclusion and exclusion criteria listed
below were invited to participate. Patients with a minimum age of
18 years and able to return completed 4-day food record were
eligible, irrespective of gender, the underlying primary renal disease,
presence of CVD, diabetes mellitus, or traditional atherogenic risk
factors. Malignancy in the past 6 months, abnormal liver function, a
history of gastrointestinal disease or metabolic disease, or an active
infection were the exclusion criteria. Additional exclusion criteria were
use of coumarin derivatives, anticonvulsants (such as phenytoin,
carbamazepine, and phenobarbital), which may influence vitamin K
metabolism, and use of vitamin K supplements. Data were obtained
on demographic, clinical, and dialysis-specific characteristics during
interview and from review of patient’s files. Informed consent was
obtained from all participants and the study was approved by the
local medical ethics committee. During the inclusion period, there
were 163 patients on regular in-center HD. Of these, 40 patients
met all inclusion and exclusion criteria and were included in the
study.
Vitamin K intake
Energy and nutrient intake were estimated by registration of all food
items consumed, including beverages, and the amount consumed
during 4 non-consecutive days in food records by the patients,
within a time period of 2 weeks. A food record was used, because
our aim was to estimate absolute intake of vitamin K rather than
relative intake as measured by a food-frequency questionnaire. As
this method is completely open ended, it can accommodate any
food or food combination reported by the subject. The food record
only had pre-specified sections for breakfast, lunch, dinner, and
snacks. All participants received verbal and written instructions before
receiving the 4-day food record. The food record consisted of 2 week
days and 1 weekend day, during which the patient did not undergo
HD treatment, and 1 week day during which the patient underwent
HD treatment (‘dialysis day’). The 4-day food records were collected
on other days than the days before and of the blood drawn.
Food records were analyzed using a nutrient software program
(part of Evry-Dietist, Ensemble BV, Zoetermeer, The Netherlands),
which is based on the Dutch national food compositions (NEVO)
table. Energy and nutrient intake were calculated using the 2006
version of the Dutch Food Composition Database (NEVO), which
contains data on the nutritional composition of approximately 2780
foods (www.rivm.nl/nevo_en/). Concentrations of vitamin K1 and K2
(MK-4 through MK-10) of 260 foods have been added to the NEVO
(2006) food database, as described previously.12 All nutrients were
adjusted for total energy intake by using the residual method.27 Owing
to the variance intake on week, weekend, and dialysis days, intake was
measured on non-consecutive days on 1 dialysis day, 2 separate week
days, and 1 weekend day. These intake measurements were weighted to
reflect their frequency in a 2-week period. This resulted in the
following weightings: 6/14 for weekdays, 3/14 for weekend days, and 5/
14 for dialysis days. In our study population, vegetables contributed
71% of vitamin K1 intake, cheese contributed 59%, milk products
14%, and meat 18% of vitamin K2 intake.
27
Vitamin K status
Vitamin K status was assessed by measurements of circulating
vitamin K1 and K2 (menaquinones (MK)-4 through MK-10), and
the vitamin K–dependent proteins PIVKA-II, dp-ucMGP, ucOC, and
cOC. Venous blood samples were taken before the initiation of a HD
session after the 2-day dialysis-free interval. Participants were asked to
adhere to their dietary habits, but to refrain from consumption of
vitamin K-containing food items (e.g., green vegetables and
fermented food products) the evening before and the day of blood
withdrawal. Before serum preparation, blood was kept for 20 min at
room temperature. Plasma and serum were prepared by standard
centrifugation and stored at 80 1C until testing.
The circulating concentrations of vitamin K species (vitamin K1,
MK-4 through MK-10) were measured using reversed phase high-
performance liquid chromatography as described previously.11
PIVKA-II levels were measured with the ASSERACHROM
PIVKA-II kit (Diagnostica Stago, Asnie`res-sur-Mer, France). This
ELISA is based on mouse monoclonal F(ab’)2 fragments specific for
PIVKA-II, without reactivity with native prothrombin.
Circulating dp-ucMGP levels were determined in plasma using a
dual-antibody ELISA (VitaK BV, Maastricht, The Netherlands). In
this assay, the capture antibody is directed against the non-
phosphorylated MGP sequence 3–15 and the detection antibody
against the uncarboxylated MGP sequence 35–49. This assay was
shown to be particularly suited to assess vascular vitamin K status.15
Markers used to evaluate the carboxylation status of circulating
OC were ucOC, cOC, and the ratio between ucOC and cOC (ucOC/
cOC). Both ucOC and cOC levels were measured with ELISAs based
conformation-specific OC antibodies (Takara, Shiga, Japan).
Other biochemical measurements, including calcium, phosphorus,
cholesterol, triglycerides, alkaline phosphatase, and parathyroid
hormone were performed using standard laboratory techniques.
Statistical analysis
Normally and non-normally distributed continuous variables are
presented as mean±s.d. or as median (range), respectively, and
categorical variables as numbers and frequencies. Differences in
vitamin K intake between day-types (week, weekend, and dialysis
days) were analyzed with Kruskal–Wallis and Mann–Whitney
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U-tests. Within-group differences in vitamin K intake and param-
eters of vitamin K status were analyzed with Kruskal–Wallis and
Mann–Withney U-tests. Bonferroni correction was applied for
multiple comparisons. Bivariate correlation analysis was performed
using the Pearson correlation coefficient for normally distributed
data and Spearman correlation coefficient for non-normally
distributed data. A P-value of o0.05 was considered to be stati-
stically significant; reported P-values are based on two-tailed tests of
statistical significance. All statistical analyses were conducted using
SPSS version 15.0 for Windows (SPSS, Chicago, IL).
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